New Paper: Validation of PGT-P for disease risk, presentation of first clinical PGT-P cycles

Titled "Utility and first clinical application of screening embryos for polygenic disease risk reduction", ORIGINAL RESEARCH ARTICLE published in Frontiers in Endocrinology

Article linked here.



Utility and first clinical application of screening embryos for polygenic disease risk reduction


 Nathan R. Treff1*,  Jennifer Eccles1, Louis Lello1, 2, Elan Bechor1, Jeffrey Hsu1, Kathryn Plunkett1, Raymound Zimmerman1, Bhavini Rana1, Artem Samoilenko1, Steven Hsu2 and  Laurent C. Tellier1, 2


  • 1Genomic Prediction, Inc., United States
  • 2Michigan State University, United States


For over 2 decades preimplantation genetic testing (PGT) has been in clinical use to reduce the risk of miscarriage and genetic disease in patients with advanced maternal age and risk of transmitting disease. Recently developed methods of genome-wide genotyping and machine learning algorithms now offer the ability to genotype embryos for polygenic disease risk with accuracy equivalent to adults. In addition, contemporary studies on adults indicate the ability to predict polygenic disorders with risk equivalent to monogenic disorders. Existing biobanks provide opportunities to model the clinical utility of polygenic disease risk reduction among sibling adults. Here, we provide a mathematical model for the use of embryo screening to reduce the risk of type 1 diabetes. Results indicate a 44%-72% reduced risk with blinded genetic selection of one sibling. The first clinical case of polygenic risk scoring in human preimplantation embryos from patients with a family history of complex disease is also reported. In addition to these data, several common and accepted practices place PGT for polygenic disease risk in the applicable context of contemporary reproductive medicine. In addition, prediction of risk for PCOS, endometriosis, and aneuploidy are of particular interest and relevance to patients with infertility and represent an important focus of future research on polygenic risk scoring in embryos.


Keywords: Polygenic risk score, preimplantation genetic testing, Advanced maternal age, Aneuploidy, type 1 diabetes

Received: 15 Jul 2019; Accepted: 19 Nov 2019.


Copyright: © 2019 Treff, Eccles, Lello, Bechor, Hsu, Plunkett, Zimmerman, Rana, Samoilenko, Hsu and Tellier. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.


* Correspondence: Dr. Nathan R. Treff, Genomic Prediction, Inc., North Brunswick, United States, nathan@genomicprediction.com

© Genomic Prediction, 2019